In Hospital Equipment It's Goodbye Agilent, Hello Philips-Andover

With its $1.7 billion acquisition of the Healthcare Solutions Group (HSG) of Agilent Technologies, the fourth major purchase for the company in less than two-and-a-half years, Philips Medical Systems believes it now has the muscle to compete long term with its principle competitors in the global hospital equipment market: GE Medical Systems and Siemens Medical Systems. As patient monitoring and clinical systems have become more integrated, drawing information in multiple formats from many hospital departments and remote locations, hospitals increasingly want to work with a single supplier, driving consolidation. Being the winner, or highly competitive, on a product-to-product basis, as Philips has been in its markets, is no longer enough. Thus, to maintain a level playing field with GE and Siemens, which have each been bulking up via acquisition this year--notably Siemens with Acuson and Shared Medical Systems, and GE with Critikon, plus many smaller purchases--Philips has also been expanding the size, breadth, and depth of its offerings. For Agilent, the deal puts to rest a half-year's worth of speculation about what it would do with HSG, which had experienced declining orders and revenues in the last two quarters, leading to an August 2000 restructuring.

With its $1.7 billion acquisition of the Healthcare Solutions Group (HSG) of Agilent Technologies Inc. [See Deal], the fourth major purchase for the company in less than two-and-a-half years, Philips Medical Systems Inc. , a division of Philips NV , believes it now has the muscle to compete long term with its principle competitors in the global hospital equipment market: GE Medical Systems , a division of General Electric Co. , and Siemens Medical Systems Inc. , a division of Siemens AG .

As patient monitoring and clinical systems have become more integrated, drawing information in multiple formats from many hospital departments and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By 

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.